Retina Specialist, Midwest Eye Institute, Indianapolis, IN
Ophthalmology
Dr. Thomas A. Ciulla, MD
|
|
Give Review
Thomas A. Ciulla is an expert in the field of Ophthalmology. He studied medicine at University of California San Francisco School of Medicine. University of California San Francisco School of Medicine is a top medical college. University of California San Francisco School of Medicine has a rank of 3 in research and a 3 in primary care He received 18 awards: "Indianapolis Monthly", "American Academy of Ophthalmology", "Best Paper Award", "Honor Award", "Achievement Award", "Career Development Award, 1999-2002", "Best Doctors in Indianapolis", "Professor of the Year Award, 1996-1997", "Heed Ophthalmic Foundation Fellowship, 1995-1996", "Alpha Omega Alpha, 1987-1991", "The Faculty-Alumni Award, 1987-1991", "Summer research grants", "B.A. in chemistry Magna Cum Laude, 1982-1986", "Pescosolido Scholarship (given to a scholar-athlete), 1982-1986", "The Devlin Scholarship (each year)", "Fellow (FAAO)", "Most Compassionate Doctor" and "Deans List". Doctor Thomas A. Ciulla, MD is a published doctor. He has 64 papers published. The most current publication "Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy." He accepts Medicare.
Publications
- Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for Diabetic macular edema.
- Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related Macular degeneration: year 1 results of the FOCUS Study.
- Treatment strategies for refractory Diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy.
- RANIBIZUMAB FOR Diabetic MACULAR EDEMA REFRACTORY TO MULTIPLE PRIOR TREATMENTS.
- Factors affecting visual outcomes in patients with Diabetic macular edema treated with ranibizumab.
- Treatment of Diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide imp...
- Current and future treatment options for nonexudative and exudative age-related Macular degeneration.
- Dexamethasone Intravitreal Implant in Combination with Laser Photocoagulation for the Treatment of Diffuse Diabetic Macular Edema.
- Ranibizumab for Edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment.
- Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants.
- Incidence of cytomegalovirus retinitis in the era of highly active antiretroviral therapy.
- Association of host genetic risk factors with the course of cytomegalovirus retinitis in patients infected with human immunodeficiency virus.
- Ranibizumab and bevacizumab for neovascular age-related Macular degeneration.
- Response to: Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with Retinal vein occlusion by Schroff et al..
- Ranibizumab for choroidal neovascularization secondary to causes Other than age-related macular degeneration: a phase I clinical trial.
- Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: five-year outcomes.
- Two-year outcomes of the ranibizumab for Edema of the mAcula in diabetes (READ-2) study.
- Excess mortality in patients with AIDS in the era of highly active antiretroviral therapy: temporal changes and risk factors.
- Sustained Ocular delivery of fluocinolone acetonide by an intravitreal insert.
- Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process.
- Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for Diabetic macular edema.
- Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with Retinal vein occlusion: 6 months of follow-up.
- Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study.
- SCORE Study Report 7: incidence of intravitreal silicone oil droplets associated with staked-on vs luer cone syringe design.
- Intravitreal bevacizumab for Choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome.
- A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with Macular edema secondary to cen...
- A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with Macular Edema secondary to b...
- Pharmacologic therapies for Diabetic retinopathy and Diabetic macular edema.
- Antivascular endothelial growth factor therapy for neovascular age-related Macular degeneration.
- Anti-vascular endothelial growth factor therapy for neovascular ocular diseases Other than age-related macular degeneration.
- Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related Macular degeneration: Two-year results of the ANCHOR study.
- Age-related Macular degeneration and the aging eye.
- Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of Diabetic macular edema.
- How the Diabetic eye loses vision.
- The relationship between retrobulbar and Choroidal hemodynamics in non-neovascular age-related macular degeneration.
- Corticosteroids as antiangiogenic agents.
- Ranibizumab for treatment of neovascular age-related Macular degeneration: a phase I/II multicenter, controlled, multidose study.
- Oral administration of lumiracoxib reduces Choroidal neovascular membrane development in the rat laser-trauma model.
- Human vitreous distribution of linezolid after a single oral dose.
- Current and future pharmacological intervention for Diabetic retinopathy.
- Anastomotic vessels remain viable after photodynamic therapy in primate models of Choroidal neovascularization.
- New and classic insights into presumed Ocular histoplasmosis syndrome and its treatment.
- Future pharmacological treatment options for nonexudative and exudative age-related Macular degeneration.
- PharmacOtherapy for diabetic retinopathy.
- Macular pigment density and aging, assessed in the normal elderly and those with Cataracts and age-related macular degeneration.
- Evaluation of photopoint photosensitizer mv6401, indium chloride methyl pyropheophorbide, as a photodynamic therapy agent in primate choriocapillaris and laser-induced...
- Corticosteroids in posterior segment disease: an update on new delivery systems and new indications.
- Laser trabecular sclerosis for chronic hypotony after vitreoRetinal surgery.
- The squirrel monkey: characterization of a new-world primate model of experimental Choroidal neovascularization and comparison with the macaque.
- Diagnostic imaging of Retinal disease.
- Squalamine lactate reduces Choroidal neovascularization in a laser-injury model in the rat.
- Diabetic retinopathy and Diabetic macular edema: pathophysiology, screening, and novel therapies.
- Recent advances in the treatment of exudative age-related macular degeneration, including transpupillary thermOtherapy.
- Leber congenital amaurosis associated with optic disk neovascularization and vitreous Hemorrhage.
- Proton therapy for exudative age-related Macular degeneration: a randomized, sham-controlled clinical trial.
- Ocular perfusion abnormalities in diabetes.
- Novel approaches for Retinal drug delivery.
- An update on photodynamic therapy in age-related Macular degeneration.
- Treating cytomegalovirus retinitis-related Retinal detachment by combining silicone oil tamponade and ganciclovir implant.
- Localization of rose bengal, aluminum phthalocyanine tetrasulfonate, and chlorin e6 in the rabbit eye.
- Choroidal perfusion perturbations in non-neovascular age related macular degeneration.
- Macular pigment density is reduced in obese subjects.
- Bacterial Endophthalmitis prophylaxis for cataract surgery: an evidence-based update.
Schools
University Of California San Francisco School Of Medicine
Harvard Med School
Tufts Med School
Procedures Preformed
- Cataract Removal Surgery
- Destruction of Lesion of Retina and Choroid
- Repair of Retinal Detachment or Retinal Tear
- Vitrectomy (incl. Macular Hole Repair)
Conditions Treated
- Acute Endophthalmitis
- Aphakia and Other Disorders of Lens
- Benign Neoplasm of Choroid
- Benign Neoplasm of Eye
- View All
Doctors Specialties
- Ophthalmology
Accepted Insurances
Awards
- Indianapolis Monthly
- American Academy of Ophthalmology
- Best Paper†Award
- Honor Award
- Achievement Award
- Career Development Award, 1999-2002
- Best Doctors in Indianapolis
- Professor of the Year Award, 1996-1997
- Heed Ophthalmic Foundation Fellowship, 1995-1996
- Alpha Omega Alpha, 1987-1991
- The Faculty-Alumni Award, 1987-1991
- Summer research grants
- B.A. in chemistry Magna Cum Laude, 1982-1986
- Pescosolido Scholarship (given to a scholar-athlete), 1982-1986
- The Devlin Scholarship (each year)
- Fellow (FAAO)
- Most Compassionate Doctor
- Dean’s List
Education
-
Tufts Medical Center -
University of California San Francisco School of Medicine -
Harvard College
Drug Facts
| NPI NUMBER | 1770585838 | |
| NPPES Provider LastName | CIULLA | |
| NPPES Provider FirstName | THOMAS | |
| NPPES Provider ZIPCode | 462901017 | |
| NPPES Provider State | IN | |
| Specialty Description | Ophthalmology | |
| Total Claim Count | 394.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1770585838 |
| Last Name Of The Provider | CIULLA |
| First Name Of The Provider | THOMAS |
| View All |
Similar Doctors
|
|
Dr. Uma D. Chaluvadi, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. William E. Whitson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kathryn M. Haider, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Louis B. Cantor, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Elliott A. Yolles, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen M. Johnson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. George E. McCord, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert J. Boeglin Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David V. Poer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert M. Troyer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thierry H. Wilbrandt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yuri F. McKee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Earl E. Lanter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hemang C. Patel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Suzanna Billinghurst, MD |
|
|
Dr. Caroline L. Denwood, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Adam W. Brazus, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Allison A. Pernic, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ryan J. Wise, MD |